Clinical research priorities in renal cell carcinoma: Renal cell carcinoma chemoprevention strategies including target populations, proposed agents, and clinical trial designs - Workgroup no. 6

Cancer

Volumn 80, Issue 5, 1997, Pages 999-1001

  Hanash, Kamal A ^a   Aquilina, Joseph W ^b   Barrett, David M ^b   Blute, Michael L ^b   Cockett, Abraham T K ^b   Corica, Federico A ^b   Hillman, Gilda G ^b   Zbar, Berton ^b   Zhuang, Zhengping ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CANCER VACCINE; CYTOKINE; DEXVERAPAMIL; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA B7 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RETINOID;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; DIET SUPPLEMENTATION; GENE THERAPY; GENETIC PREDISPOSITION; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTO ONCOGENE; SUBCUTANEOUS DRUG ADMINISTRATION; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; CHEMOPREVENTION; CLINICAL TRIALS; GENE THERAPY; HEALTH PRIORITIES; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; PATIENT SELECTION; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 0030799591     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970901)80:5<999::AID-CNCR29>3.0.CO;2-Q     Document Type: Article

References (14)

1. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc, 1976;35:1332-8.
2. Everitt JI, Goldsworthy TL, Wolf DC, Walker CL. Hereditary renal cell carcinoma in the Eker rat: a rodent familial cancer syndrome. J Urol 1992;148:1932-6.
3. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcut ML, et al. Identification of the von Hippel-Lindau Disease tumor supressor gene. Science 1993;260:1317-20.
4. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 1995;273(7):564-70.
5. Haas GP, Hillman GG. Update on the role of immunotherapy in the management of Kidney cancer. Cancer Causes Control 1996;3:66-71.
6. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-32.
7. Pierce WC, Belldegrun A, Figlin RA. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. Seminar Oncol 1995;22(1):74-80.
8. Marincola FM, White DE, Wise AP, Rosenberg SA. Combination therapy with Interferon alpha-2α and interleukin-2 for the treatment of metastatic cancer. Clinic Oncol 1995; 13(5):1110-22.
9. Hanninen LE, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996;155:19-25.
10. Li X, Liu J, Park JK, Hamilton TA, Rayman P, Klein E, et al. T cells from renal cell carcinoma patients exhibit an abnormal κB-specific DNA-binding activity: a preliminary report. Cancer Res 1994;54:5424-39.
11. Brunda MJ, Luistro L, Warrier R, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-30.
12. Grabbe S, Beissert S, Schwarz T, Granstein RD. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 1995;16(3):117-21.
13. Kirchner HH, Anton P, Atzpodien J. Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol 1995;13(3):171-3.
14. Mickisch GH. Chemoresistance of renal cell carcinoma: 1986-1994. World J Urol 1994;12:214-23.